In total, six patients developed E. coli infections after receiving stool transplants. One other did not contract an infection, but died from underlying medical conditions. The FDA said it suspects the stool, donated from three separate donors, contained infection-causing bacteria. OpenBiome identified two different types of E. coli in stool samples from the six living patients. The FDA said it is still not known if the stool transplant contributed to the patient’s death.
OpenBiome is collaborating with the FDA to change its screening program and ensure stool is properly screened for pathogens. OpenBiome issued a recall on all material from the three donors, and all affected facilities have destroyed the recalled units.
“Across over 55,000 treatments shipped, these six cases are the first likely transmission of pathogens from our materia,” a spokesperson for OpenBiome told Becker’s via email. “We have never received a report of a patient death definitively caused by OpenBiome material.”
Editor’s note: This article was updated March 13 at 9:00 a.m. and March 16 at 8:15 a.m. to provide additional information.
More articles on patient safety and outcomes:
47 practices for safer care from AHRQ
How Northwell improved resuscitation outcomes in the ED
Top 10 patient safety concerns of 2020 from ECRI Institute
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
